Cerecyte Microcoils Featured in Key Presentations at the World Federation of Interventional Neuroradiology.

SUNNYVALE, Calif. -- Micrus Endovascular Corporation (Nasdaq:MEND) today announced that its Cerecyte(R) microcoils appear to improve intracranial aneurysm occlusion rates compared with bare platinum microcoils, according to two studies presented at the 8th Congress of the World Federation of Interventional and Therapeutic Neuroradiology held October 19-23 in Venice, Italy. Micrus Endovascular's Cerecyte microcoils incorporate a bioactive filament with the Company's proprietary, three-dimensional microcoils that easily deploy within a cerebral aneurysm, forming a scaffold that conforms to a wide diversity of aneurysm shapes and sizes.

In the first study presented by Dr. Martin Bendszus of the University of Wurzburg, Germany, 18 of 26 patients treated for cerebral aneurysms with Cerecyte coils obtained complete aneurysm occlusion at the completion of the procedure. This number increased to 23 patients at six months following the procedure. Dr. Bendszus reported that the percentage of patients with complete occlusion immediately following the procedure and the percentage of aneurysms converted to complete occlusion at six-month follow up were better than in a similar group treated with bare platinum microcoils.

The second study, presented by Dr. Neil Gholkar, Newcastle, United Kingdom, produced similar results in a population of 30 patients treated with Cerecyte microcoils. Dr. Gholkar concluded that Cerecyte resulted in occlusion rates better than published results, and added that no re-treatments were required in the Cerecyte treated group.

"We are very pleased that the presented data appears to support what we believe to be the underlying clinical benefits of our Cerecyte microcoils," stated John Kilcoyne, CEO of Micrus Endovascular. "We believe the design of Cerecyte microcoils enables the endovascular specialist to have the same framing and handling characteristics of our bare platinum microcoils, while also delivering the potential advantages of Cerecyte. We look forward to more Cerecyte clinical data and publications from individual clinical series as well as the results of the Cerecyte Coil Trial that we initiated earlier this month."

About Micrus Endovascular Corporation

Micrus Endovascular develops, manufactures and markets both implantable and disposable medical devices used in the treatment of cerebral vascular diseases. Micrus products are used by interventional neuroradiologists and neurosurgeons primarily to treat cerebral aneurysms responsible for hemorrhagic stroke, a significant cause of death in the United States. The Micrus product line enables physicians to gain access to the brain in a minimally invasive manner through the vessels of the circulatory system. Micrus' proprietary, three-dimensional microcoils are unique in that they automatically deploy within the aneurysm, forming a scaffold that conforms to a wide diversity of aneurysm shapes and sizes. Micrus also sells accessory devices and products used in conjunction with its microcoils. For more information visit www.micruscorp.com.

Forward-Looking Statements

Micrus Endovascular, from time to time, may discuss forward-looking information and this press release contains or may contain forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements can be identified by terminology such as "may," "will," "should," "intends," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential," or "continue," or the negative of these terms or other comparable terminology. Except for the historical information contained in this release, all forward-looking statements are predictions by the Company's management and are subject to various risks and uncertainties that may cause results to differ from management's current expectations. Such factors include the Company's dependence upon the increased use of embolic coiling as a procedure to treat cerebral aneurysms, achieving profitability in light of its limited operating history and history of significant operating losses, the Company's involvement in patent litigation with Boston Scientific Corporation, fluctuations in quarterly operating results, developing new products or product enhancements that will be accepted by the Company's market, complying with applicable state, federal and international regulations related to sales of medical devices and governing our relationships with physicians and other consultants, competing and gaining market share in a highly competitive market segment with large, well-established medical device manufacturers with significant resources, obtaining on a timely basis clearances from the U.S. Food and Drug Administration (and similar regulatory agencies outside the United States) and approvals for our future products or product enhancements, and other risks as detailed from time-to-time in the Company's Quarterly Report on Form 10-Q filed with the SEC on August 15, 2005 and the other reports and filings with the Securities and Exchange Commission under the Securities Act of 1933 and the Securities and Exchange Act of 1934. All forward-looking statements, if any, in this release represent the Company's judgment as of the date of this release. The Company disclaims, however, any intent or obligation to update forward-looking statements.